369 related articles for article (PubMed ID: 25445343)
21. Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C.
Zeng Y; Li W; Li J; Wang J; Zhou B; Zhang J; Liu S; Wu Y; Hou J; Zhou Y
Arch Virol; 2012 Jun; 157(6):1113-21. PubMed ID: 22426896
[TBL] [Abstract][Full Text] [Related]
22. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
Akhtar N; Bilal M; Rizwan M; Khan MA; Khan A
Asian Pac J Cancer Prev; 2015; 16(3):1037-40. PubMed ID: 25735327
[TBL] [Abstract][Full Text] [Related]
23. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
[TBL] [Abstract][Full Text] [Related]
24. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
[TBL] [Abstract][Full Text] [Related]
25. Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure.
Jagjit Singh GK; Kaye S; Abbott JC; Boesecke C; Rockstroh J; McClure MO; Nelson M
HIV Clin Trials; 2018 Apr; 19(2):46-51. PubMed ID: 29493385
[TBL] [Abstract][Full Text] [Related]
26. Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors.
Wright-Minogue J; Yao N; Zhang R; Butkiewicz NJ; Baroudy BM; Lau JY; Hong Z
J Hepatol; 2000 Mar; 32(3):497-504. PubMed ID: 10735621
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
[TBL] [Abstract][Full Text] [Related]
28. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
[TBL] [Abstract][Full Text] [Related]
29. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Wyles DL; Gutierrez JA
J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
[TBL] [Abstract][Full Text] [Related]
30. Virological Response to Conventional Interferon Therapy Combined with Ribavirin against Various HCV Genotypes in Khyber Pakhtunkhwa, Pakistan.
Ali S; Ahmad B; Ali I; Mahmood N; Anwar N; Saeedi I; Afridi JZ
Asian Pac J Cancer Prev; 2016; 17(5):2407-10. PubMed ID: 27268605
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of interferon alpha with ribavirin for treatment of chronic Hepatitis C].
Tao J; Liu J; Pu D; Lei H
Zhonghua Gan Zang Bing Za Zhi; 2011 Sep; 19(9):683-5. PubMed ID: 22152384
[TBL] [Abstract][Full Text] [Related]
32. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
[TBL] [Abstract][Full Text] [Related]
33. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.
Donlin MJ; Cannon NA; Aurora R; Li J; Wahed AS; Di Bisceglie AM; Tavis JE;
PLoS One; 2010 Feb; 5(2):e9032. PubMed ID: 20140258
[TBL] [Abstract][Full Text] [Related]
34. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
35. HCV non-structural NS4A protein of genotype 3a induces mitochondria mediated death by activating Bax and the caspase cascade.
Javed F; Manzoor S
Microb Pathog; 2018 Nov; 124():346-355. PubMed ID: 30179714
[TBL] [Abstract][Full Text] [Related]
36. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
[TBL] [Abstract][Full Text] [Related]
37. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
[TBL] [Abstract][Full Text] [Related]
38. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1354-62. PubMed ID: 18551609
[TBL] [Abstract][Full Text] [Related]
39. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
[TBL] [Abstract][Full Text] [Related]
40. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.
Yuan HJ; Jain M; Snow KK; Gale M; Lee WM;
J Viral Hepat; 2010 Mar; 17(3):208-16. PubMed ID: 19656286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
